This suggests that, apart from HER2 expression, immunomodulation may contribute to the persistence of the therapeutic effects of T-DXd in gastric cancer, as baseline analysis showed the lack of correlation between HER2 expression and any immune parameters. The gene discussed is ERBB2; the disease is gastric cancer.